keyword
MENU ▼
Read by QxMD icon Read
search

mepolizumab

keyword
https://www.readbyqxmd.com/read/29766394/treatment-of-eosinophilic-granulomatosis-with-polyangiitis-a-review
#1
Loïc Raffray, Loïc Guillevin
Eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome) is a rare type of anti-neutrophil cytoplasm antibody-associated vasculitis. Nevertheless, eosinophilic granulomatosis with polyangiitis stands apart because it has features of vasculitis and eosinophilic disorders that require targeted therapies somewhat different from those used for other anti-neutrophil cytoplasm antibody-associated vasculitides. Considerable advances have been made in understanding the underlying pathophysiology of eosinophilic granulomatosis with polyangiitis that have highlighted the key role of eosinophils and opened new therapeutic opportunities...
May 15, 2018: Drugs
https://www.readbyqxmd.com/read/29751154/long-term-clinical-outcomes-of-high-dose-mepolizumab-treatment-for-hypereosinophilic-syndrome
#2
Fei Li Kuang, Michael P Fay, JeanAnne Ware, Lauren Wetzler, Nicole Holland-Thomas, Thomas Brown, Hector Ortega, Jonathan Steinfeld, Paneez Khoury, Amy D Klion
BACKGROUND: Conventional therapies for hypereosinophilic syndromes (HES) have variable efficacy and carry significant long-term toxicities. Anti-IL5 (mepolizumab) therapy has a glucocorticoid (GC)-sparing effect in GC-sensitive HES, but the efficacy of mepolizumab in treatment-refractory HES patients with severe disease has not been examined to date. OBJECTIVE: To identify predictors of response to mepolizumab in subjects with severe treatment-refractory HES and compare long-term outcomes in these subjects to HES subjects treated with conventional therapies...
May 8, 2018: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/29736895/cost-effectiveness-of-biological-asthma-treatments-a-systematic-review-and-recommendations-for-future-economic-evaluations
#3
REVIEW
R Brett McQueen, Danielle N Sheehan, Melanie D Whittington, Job F M van Boven, Jonathan D Campbell
BACKGROUND: Recently developed asthma biological therapies have been shown to provide relief for severe asthma patients not controlled by inhaled treatment. Given the relatively high costs of biological therapies, cost-effectiveness analyses (CEAs) may be required as a prerequisite for coverage and reimbursement. OBJECTIVE: We aimed to systematically review published literature on the economic impact of biological asthma therapies and to identify key drivers that impact cost-effectiveness in order to provide recommendations for future economic evaluations...
May 8, 2018: PharmacoEconomics
https://www.readbyqxmd.com/read/29733738/case-study-a-combination-of-mepolizumab-and-omaluzimab-injections-for-severe-asthma
#4
Rejmon Dedaj, Lindie Unsel
A Combination of Mepolizumab and Omaluzimab injections for severe asthma. INTRODUCTION: Patients with severe persistent asthma account for a large proportion of asthma morbidity and health care expenditures. In this case report we describe the use of a combination of omalizumab and mepolizumab in severe asthma with elevated IgE levels and eosinophilic phenotype. CASE STUDY: We are treating a 55 year old woman with severe persistent eosinophilic asthma and elevated IgE levels...
May 7, 2018: Journal of Asthma: Official Journal of the Association for the Care of Asthma
https://www.readbyqxmd.com/read/29715561/low-blood-eosinophil-counts-are-not-always-a-reliable-marker-of-clinical-response-to-mepolizumab-in-severe-asthma
#5
Iñigo Ojanguren, Simone Chaboillez, Catherine Lemiere
No abstract text is available yet for this article.
April 28, 2018: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/29713354/severe-eosinophilic-asthma-in-primary-care-in-canada-a-longitudinal-study-of-the-clinical-burden-and-economic-impact-based-on-linked-electronic-medical-record-data
#6
Don Husereau, Jason Goodfield, Richard Leigh, Richard Borrelli, Michel Cloutier, Alain Gendron
Background: Stratification of patients with severe asthma by blood eosinophil counts predicts responders to anti-interleukin (IL)-5 (mepolizumab and reslizumab) and anti-IL-5 receptor α (benralizumab) therapies. This study characterized patients with severe asthma who could qualify for these biologics in a primary care setting. Methods: We retrospectively selected patients from July 1, 2010, to June 30, 2014, using a linked electronic medical records (EMR) database (IMS Evidence 360 EMR Canada) for > 950,000 patients in primary care in Ontario, Canada...
2018: Allergy, Asthma, and Clinical Immunology
https://www.readbyqxmd.com/read/29684570/mepolizumab-in-the-treatment-of-severe-eosinophilic-asthma-results-from-a-physician-in-the-field
#7
Ronald A Strauss, Nesreen Jawhari
No abstract text is available yet for this article.
April 20, 2018: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/29682504/targeting-the-interleukin-5-pathway-for-treatment-of-eosinophilic-conditions-other-than-asthma
#8
REVIEW
Florence Roufosse
Improved understanding of the contribution of eosinophils to various chronic inflammatory conditions, most notably allergic asthma, has encouraged development of monoclonal antibodies specifically targeting mediators and surface receptors involved in eosinophil expansion and activation. The pivotal role of interleukin-5 (IL-5) in eosinophil biology, its high specificity for this leukocyte subset, and its involvement in the majority of eosinophilic conditions make it a very enticing target for treatment of eosinophil-mediated disorders...
2018: Frontiers in Medicine
https://www.readbyqxmd.com/read/29672188/effect-of-inhaled-corticosteroid-use-on-weight-bmi-in-pediatric-patients-with-moderate-severe-asthma
#9
Jennifer Han, John Nguyen, Yuna Kim, Bob Geng, Gale Romanowski, Lawrence Alejandro, James Proudfoot, Ronghui Xu, Sydney Leibel
OBJECTIVES: Assess the relationship between inhaled corticosteroid use (ICS) and weight (BMI) in pediatric patients with moderate-severe asthma. Assess if the number of emergency department (ED) visits correlates with overall BMI trajectory. Assess the trend of prescribing biologic therapy in pediatric patients with moderate-severe asthma and determine its relationship with weight (BMI). METHODS: A retrospective chart review was performed on 93 pediatric patients with moderate-severe asthma to determine the relationship between ICS use and weight (BMI), biologic therapy and BMI, and number of ED visits and BMI trajectory...
April 19, 2018: Journal of Asthma: Official Journal of the Association for the Care of Asthma
https://www.readbyqxmd.com/read/29653234/mepolizumab-use-post-approval-academic-practice-experience
#10
Mariel R Benjamin, Bruce S Bochner, Anju T Peters
No abstract text is available yet for this article.
April 10, 2018: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/29611207/immunological-and-hematological-effects-of-il-5-r%C3%AE-targeted-therapy-an-overview
#11
REVIEW
M Hassani, L Koenderman
IL-5 is an important cytokine for priming and survival of mature eosinophils, and for proliferation and maturation of their progenitors. Hence, IL-5(Rα) targeting will be increasingly used in diseases where eosinophils are the key immune effector cells such as eosinophilic asthma (EA), hyper eosinophilic syndrome (HES), eosinophilic esophagitis (EE) and eosinophilic granulomatosis with polyangitis (EGPA). Therefore, several neutralizing monoclonal antibodies directed against IL-5 (mepolizumab and reslizumab) and its receptor IL-5Rα (benralizumab) have found or will find their way to the clinic...
April 3, 2018: Allergy
https://www.readbyqxmd.com/read/29611001/eosinophilic-granulomatosis-with-polyangiitis-newer-therapies
#12
REVIEW
Erika P Navarro-Mendoza, Gabriel J Tobón
PURPOSE OF REVIEW: Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic disseminated vasculitis associated with extravascular granulomas in patients suffering from asthma and tissue eosinophilia. Current therapies to achieve remission and prevent relapse include glucocorticoids and immunosuppressants like cyclophosphamide. RECENT FINDINGS: With the right treatment, clinical prognosis is favorable, so concerted efforts have been made in recent years to find new alternatives for treating severe EGPA...
April 2, 2018: Current Rheumatology Reports
https://www.readbyqxmd.com/read/29609004/emerging-biological-therapies-for-treating-chronic-obstructive-pulmonary-disease-a-pairwise-and-network-meta-analysis
#13
Paola Rogliani, Maria Gabriella Matera, Ermanno Puxeddu, Marco Mantero, Francesco Blasi, Mario Cazzola, Luigino Calzetta
Inflammation in chronic obstructive pulmonary disease (COPD) is often corticosteroid resistant and, thus, alternative anti-inflammatory approaches are needed. Since it is still not clear whether blocking specific pro-inflammatory factors may provide clinical benefit in COPD, we have performed a meta-analysis to quantify the impact of monoclonal antibodies (mABs) targeting the cytokine/chemokine-mediated inflammation in COPD. A pairwise and network meta-analyses were performed by extracting data from randomized clicnial trials on COPD concerning the impact of mABs vs...
March 30, 2018: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29606855/benralizumab-in-the-treatment-of-severe-asthma-design-development-and-potential-place-in-therapy
#14
REVIEW
Corrado Pelaia, Alessandro Vatrella, Andrea Bruni, Rosa Terracciano, Girolamo Pelaia
Asthma is a widespread and heterogeneous inflammatory disease of the airways, which is characterized by several different phenotypes and endotypes. In particular, eosinophilic airway inflammation is a common pathologic trait of both allergic and nonallergic asthma. The key cytokine responsible for maturation, activation, recruitment, and survival of eosinophils is interleukin (IL)-5, which is mainly produced by T helper 2 (Th2) lymphocytes and group 2 innate lymphoid cells. Therefore, for uncontrolled patients with severe eosinophilic asthma, who are not fully responsive to corticosteroids, IL-5 represents a very important molecular target for add-on biological therapies...
2018: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/29587693/a-case-of-allergic-bronchopulmonary-aspergillosis-successfully-treated-with-mepolizumab
#15
Takeshi Terashima, Taro Shinozaki, Eri Iwami, Takahiro Nakajima, Tatsu Matsuzaki
BACKGROUND: Allergic bronchopulmonary aspergillosis (ABPA) is an allergic pulmonary disease comprising a complex hypersensitivity reaction to Aspergillus fumigatus. Clinical features of ABPA are wheezing, mucoid impaction, and pulmonary infiltrates. Oral corticosteroids and anti-fungal agents are standard therapy for ABPA, but long-term use of systemic corticosteroids often causes serious side effects. CASE PRESENTATION: A 64-year-old woman was diagnosed with ABPA based on a history of bronchial asthma (from 40 years of age), elevated total IgE, the presence of serum precipitating antibodies and elevated specific IgE antibody to A...
March 27, 2018: BMC Pulmonary Medicine
https://www.readbyqxmd.com/read/29583021/copd-2017-a-year-in-review
#16
Ernesto Crisafulli, Antoni Torres
In this review, we focused on original manuscripts published in the 2017 that provided additional information on the clinical and therapeutic features of the chronic obstructive pulmonary disease (COPD). We have chosen eight of these studies, collected in four topics concerning the pharmacological treatment (tiotropium) of mild-moderate patients, the pharmacological (fluticasone furoate/vilanterol/umeclidinium) and non-pharmacological treatment (non-invasive mechanical ventilation) of severe patients, the etiology of acute exacerbation of COPD involving seasonal airway pathogens and the role of eosinophils with particular interest to the monoclonal antibody directed against interleukin-5 (mepolizumab)...
March 27, 2018: COPD
https://www.readbyqxmd.com/read/29564565/imatinib-mesylate-use-in-refractory-eosinophilic-granulomatosis-with-polyangiitis-a-literature-review-and-a-case-report
#17
REVIEW
Tatiana V Beketova, Mikhail Y Volkov, Evgeniy A Naryshkin, Tatiana M Novoselova, Evgeniy L Nasonov
Recent advances in pharmacology have greatly expanded the drug repertoire for treatment of anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis. Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare multisystemic disorder, a type of the ANCA-associated vasculitis. Important features of this disease are eosinophilia and anti-myeloperoxidase ANCA presence in around 30-70% of patients. Primary therapy of EGPA includes steroids and cytotoxic drugs, e.g., cyclophosphamide, azathioprine, or methotrexate...
March 21, 2018: Clinical Rheumatology
https://www.readbyqxmd.com/read/29501519/a-retrospective-analysis-of-mepolizumab-in-subjects-with-aspirin-exacerbated-respiratory-disease
#18
Katherine L Tuttle, Kathleen M Buchheit, Tanya M Laidlaw, Katherine N Cahill
No abstract text is available yet for this article.
May 2018: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/29466544/mepolizumab-treatment-of-pediatric-eosinophilic-granulomatosis-with-polyangiitis
#19
Mathew X Joseph, Lauren E Jenkins, Michael E Wechsler, Loretta S Davis
No abstract text is available yet for this article.
April 1, 2018: JAMA Dermatology
https://www.readbyqxmd.com/read/29447987/escmid-study-group-for-infections-in-compromised-hosts-esgich-consensus-document-on-the-safety-of-targeted-and-biological-therapies-an-infectious-diseases-perspective-soluble-immune-effector-molecules-ii-agents-targeting-interleukins-immunoglobulins-and-complement
#20
REVIEW
K L Winthrop, X Mariette, J T Silva, E Benamu, L H Calabrese, A Dumusc, J S Smolen, J M Aguado, M Fernández-Ruiz
BACKGROUND: The present review is part of the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies. AIMS: To review, from an Infectious Diseases perspective, the safety profile of agents targeting interleukins, immunoglobulins and complement factors and to suggest preventive recommendations. SOURCES: Computer-based MEDLINE searches with MeSH terms pertaining to each agent or therapeutic family...
February 12, 2018: Clinical Microbiology and Infection
keyword
keyword
57212
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"